{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:14:35Z","timestamp":1792790075740,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128285","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:15:27Z","timestamp":1769811327000},"page":"128285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore"],"prefix":"10.1016","volume":"75","author":[{"given":"Karan","family":"Thakkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengina","family":"Kefalogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Fu","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shephali","family":"Tagore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip","family":"Dashraath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy W.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128285_bb0005","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128285_bb0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/irv.12730","article-title":"Characterisation of respiratory syncytial virus activity in children and adults presenting with acute respiratory illness at primary care clinics in Singapore, 2014-2018","volume":"14","author":"Ang","year":"2020","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2026.128285_bb0015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3201\/eid2607.190539","article-title":"Burden and cost of hospitalization for respiratory syncytial virus in young children","volume":"26","author":"Tam","year":"2020","journal-title":"Singapore Emerg. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128285_bb0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/QCO.0000000000000952","article-title":"The disease burden of respiratory syncytial virus in infants","volume":"36","author":"Munro","year":"2023","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128285_bb0025","author":"Health Sciences Authority"},{"key":"10.1016\/j.vaccine.2026.128285_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (maternal immunization study for safety and efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Simoes","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2026.128285_bb0035","series-title":"Births and fertility rates","author":"Department of Statistics Singapore","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128285_bb0040","author":"Immigration and Checkpoints Authority Singapore"},{"key":"10.1016\/j.vaccine.2026.128285_bb0045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2019.10.023","article-title":"Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants","volume":"38","author":"Rainisch","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128285_bb0050","series-title":"RSV Symposium 2022. Belfast, Northern Ireland","article-title":"Hospitalizations associated with respiratory syncytial virus among 627 U.S. children <5 years of age","author":"Curns","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128285_bb0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jpids\/piz011","article-title":"Respiratory syncytial virus-associated outpatient visits among children younger than 24 months","volume":"8","author":"Lively","year":"2019","journal-title":"J Pediatric Infectious Diseases Society"},{"key":"10.1016\/j.vaccine.2026.128285_bb0060","first-page":"146","article-title":"Respiratory Syncytial Virus\u2013Associated Hospitalizations Among Young Children: 2015\u20132016","author":"Rha","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128285_bb0065","author":"Department of Statistics Singapore"},{"key":"10.1016\/j.vaccine.2026.128285_bb0070","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.vaccine.2026.128285_bb0075","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128285_bb0080","first-page":"13","article-title":"Economic and clinical benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV in infants: a cost-effectiveness analysis for Mexico","author":"Huerta","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128285_bb0085","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2523106","article-title":"Budget impact of maternal vaccination with RSVpreF to protect privately insured infants in Dubai against respiratory syncytial virus","volume":"21","author":"Zayed","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128285_bb0090","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1016\/j.vaccine.2022.09.087","article-title":"Effectiveness of maternal pertussis vaccination in Singapore: a test-negative case-control study","volume":"40","author":"Chong","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128285_bb0095","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s11136-014-0859-5","article-title":"Population norms for the EQ-5D index scores using Singapore preference weights","volume":"24","author":"Abdin","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.vaccine.2026.128285_bb0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","article-title":"Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available","volume":"14","author":"Ara","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2026.128285_bb0105","series-title":"Meeting of the ACIP. Atlanta, United States","article-title":"Economic analysis of Nirsevimab in Pediatric populations","author":"Hutton","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128285_bb0110","series-title":"Deriving health utility weights for infants with respiratory syncytial virus (RSV)","author":"Roy","year":"2013"},{"key":"10.1016\/j.vaccine.2026.128285_bb0115","author":"Women's"},{"key":"10.1016\/j.vaccine.2026.128285_bb0120","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128285_bb0125","author":"International Monetary Fund"},{"key":"10.1016\/j.vaccine.2026.128285_bb0130","author":"Ministry of Manpower"},{"key":"10.1016\/j.vaccine.2026.128285_bb0135","author":"Department of Statistics Singapore"},{"key":"10.1016\/j.vaccine.2026.128285_bb0140","author":"Ministry of Manpower"},{"key":"10.1016\/j.vaccine.2026.128285_bb0145","author":"Department of Statistics Singapore"},{"key":"10.1016\/j.vaccine.2026.128285_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70098","article-title":"Excess respiratory hospitalisations associated with influenza, respiratory syncytial virus and SARS-CoV-2 in Singapore from 2015 to 2023","volume":"19","author":"Qi","year":"2025","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2026.128285_bb0155","first-page":"12","article-title":"Respiratory syncytial virus (RSV) disease burden among adults in primary care settings in high-income countries: a systematic review and modelling study. Open forum","author":"Li","year":"2025","journal-title":"Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128285_bb0160","first-page":"31","article-title":"Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries","author":"Nguyen-Van-Tam","year":"2022","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.vaccine.2026.128285_bb0165","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/irv.12903","article-title":"Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by respiratory intensity and impact questionnaire","volume":"16","author":"Falsey","year":"2022","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.vaccine.2026.128285_bb0170","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","article-title":"Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in European Community-dwelling older adults","volume":"226","author":"Mao","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128285_bb0175","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jval.2019.07.001","article-title":"Cost-effectiveness analysis for influenza vaccination coverage and timing in tropical and subtropical climate settings: a Modeling study","volume":"22","author":"Yue","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2026.128285_bb0180","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.3201\/eid2010.131768","article-title":"Influenza-associated hospitalizations, Singapore, 2004-2008 and 2010-2012","volume":"20","author":"Ang","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128285_bb0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcv.2019.06.005","article-title":"Seasonal influenza-associated intensive care unit admission and death in tropical Singapore, 2011-2015","volume":"117","author":"Zhang","year":"2019","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2026.128285_bb0190","series-title":"Conditions of employment","author":"Ministry of Manpower","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128285_bb0195","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128285_bb0200","doi-asserted-by":"crossref","unstructured":"Walsh EE, Perez Marc G, Zareba AM, Jiang Q, Eiras D, Patton M, et al. RENOIR trial \u2014 RSVpreF vaccine efficacy over two seasons. N Engl J Med 2024;391:1459\u201360. https:\/\/https:\/\/doi.org\/10.1056\/NEJMc2311560.","DOI":"10.1056\/NEJMc2311560"},{"key":"10.1016\/j.vaccine.2026.128285_bb0205","first-page":"12","article-title":"P-596. Immunobridging demonstrating effectiveness of the bivalent respiratory syncytial virus (RSV) prefusion F subunit vaccine in adults 18-59 years of age at high risk of severe RSV disease in a phase 3 trial: the C3671023 MONeT study results","author":"Davis","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128285_bb0210","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40121-024-00939-w","article-title":"Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States","volume":"13","author":"Molnar","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2026.128285_bb0215","author":"Agency for care effectiveness"},{"key":"10.1016\/j.vaccine.2026.128285_bb0220","article-title":"Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination","volume":"38","author":"Hodgson","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2026.128285_bb0225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jval.2022.11.014","article-title":"Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study","volume":"26","author":"Li","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2026.128285_bb0230","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: a simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2026.128285_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126418","article-title":"Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia","volume":"42","author":"Nazareno","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128285_bb0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000005817","article-title":"Preterm birth frequency and associated outcomes from the MATISSE (maternal immunization study for safety and efficacy) maternal trial of the bivalent respiratory syncytial virus prefusion F protein vaccine","volume":"145","author":"Madhi","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2026.128285_bb0245","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.60735","article-title":"Respiratory syncytial virus vaccine and Nirsevimab uptake among pregnant people and their neonates","volume":"8","author":"Blauvelt","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128285_bb0250","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.60729","article-title":"Maternal RSVpreF and infant Nirsevimab immunizations uptake during respiratory syncytial virus season","volume":"8","author":"Litman","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128285_bb0255","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128285_bb0260","doi-asserted-by":"crossref","first-page":"176","DOI":"10.12688\/gatesopenres.13201.1","article-title":"What next after GDP-based cost-effectiveness thresholds?","volume":"4","author":"Chi","year":"2020","journal-title":"Gates Open Res"},{"key":"10.1016\/j.vaccine.2026.128285_bb0265","author":"Agency for Care Effectiveness"},{"key":"10.1016\/j.vaccine.2026.128285_bb0270","doi-asserted-by":"crossref","DOI":"10.2196\/70484","article-title":"Economic evaluation of the next generation electronic medical Records in Singapore: cost-utility analysis","volume":"27","author":"Chen","year":"2025","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.vaccine.2026.128285_bb0275","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1055-9965.EPI-20-1230","article-title":"Cost-effectiveness analysis of breast Cancer screening using mammography in Singapore: a Modeling study","volume":"30","author":"Chootipongchaivat","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:51:41Z","timestamp":1772553101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":55,"alternative-id":["S0264410X26000939"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128285","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128285"}}